Imugene Reports 81% Response Rate in Azer cel Trial and Strengthened Cash Position

Imugene Limited (ASX: IMU) reported strong progress in Q3 2025, achieving an 81% overall response rate in its Phase 1b Azer-cel clinical trial for relapsed/refractory DLBCL. Of the 16 patients treated, 13 responded, including seven complete responses and six partial responses, demonstrating rapid and durable efficacy.

The company expanded trials to include CAR T-naïve indications, achieving 83% response rates in early cohorts. Financially, Imugene raised AU$24.9 million through an institutional placement and share plan, alongside receiving a AU$5.87 million R&D refund.

At quarter end, Imugene held AU$32.4 million in cash, ensuring funding into mid-2027. CEO Leslie Chong stated these milestones position the company to advance Azer-cel toward a pivotal trial in 2026 and explore strategic partnerships for its CF33 and onCARlytics programs.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com